Participated · Series A · Nov 2025

Nest Health delivers integrated medical, behavioral, and social care to entire households, replacing the fragmented experience of juggling pediatric, adult, and mental-health providers. Families receive age- and stage-aligned in-home visits augmented by virtual consultations, 24/7 clinical support, and coordinated referrals to specialists. The company’s offering spans primary care, mental-health and substance-use treatment, and social-needs assistance such as housing or utilities support. Its AI tools automate workflows before, during, and after caregiver interactions to boost care-team efficiency. Founded by Dr. Rebekah Gee, Nest Health currently operates in Louisiana and Arizona and targets Medicaid populations. The fresh $22.5 million Series A financing strengthens its balance sheet and will fund expansion of its AI-driven clinical products and geographic footprint through new and existing payer partnerships.

Participated · Equity · Nov 2025

District Cover operates an InsurTech platform that allows brokers to simplify underwriting and application workflows for urban businesses that have traditionally been underserved by legacy carriers. The company’s digital tools speed up quoting and policy issuance, helping small enterprises in city neighborhoods obtain tailored commercial coverage. District Cover plans to enhance its platform with higher total insured value (TIV) limits, upgraded quoting functionality, and a new property-only product aimed at landlords, LRO exposures, and diverse urban operations. Fresh capital will also back team growth and new municipal partnerships as the firm pushes beyond its initial New York launch. Over the past twelve months, District Cover has expanded into the Southeast, partnered with national distribution teams, processed more than 10,000 applications, and doubled its headcount. These operating milestones underscore accelerating demand for its technology-enabled approach to commercial insurance. The company has not disclosed revenue figures, but its momentum and increasing application volume point to rapid scaling potential.

Participated · Seed · Feb 2025

Afynia Laboratories builds a blood test called EndomiR that detects endometriosis by measuring a panel of circulating microRNA biomarkers and using an algorithm to compare expression profiles to surgically confirmed cases. The company spun out of McMaster University and was founded in November 2021 by researchers including Dr. Lauren Foster and Dr. Jocelyn Wessel, with Dr. Jake Prigoff as CMO. Afynia is positioning EndomiR as a non-invasive alternative to surgical diagnosis, aiming to shorten long diagnostic delays for people with pelvic pain or infertility. The startup plans to seek regulatory approval as a laboratory-developed test (LDT) in Canada and expects a Canadian launch potentially as soon as this summer, with a U.S. launch targeted for early next year. Longer-term plans include expanding the microRNA platform to additional women’s health diagnostics and exploring lower-blood-volume sampling (e.g., finger-prick) though that is not yet available. Financially, Afynia has raised a $5M seed and previously about $1.5M in pre-seed funding from academic and angel backers. Afynia Laboratories is a medtech startup developing EndomiR, a proprietary microRNA panel run by PCR and an algorithm to generate a risk score for endometriosis from a single blood tube. The company was founded in 2021 by former McMaster University researchers Lauren Foster and Jocelyn Wessels and is based in Hamilton, Ontario. Afynia has completed studies expanding to 300 patients, participated in a CIHR-funded 1,000-patient study, and reported reproducibility across labs with only ~3% variance. The startup is pursuing a laboratory-developed test pathway in a CLIA-certified laboratory, has registered with COLA, and expects full regulatory compliance by September. On the commercial side, Afynia is serving eight fertility clinics and 35 fertility doctors, has surpassed C$100,000 in revenue, and operates a lab with capacity to process 50,000 tests per year. Longer-term plans include commercializing EndomiR in Canada and the US and then rolling out additional women’s health diagnostic products covered by other patents.

Participated · Series A · Jan 2025

Twentyeight Health is a NYC-based digital-first women’s healthcare platform that makes reproductive and sexual healthcare affordable through telemedicine consultations, fast at-home deliveries, and ongoing access to providers for services such as birth control and herpes treatments. The company accepts almost every commercial insurance and Medicaid plan, positioning itself as a broadly accessible alternative to traditional care. It currently serves more than 100,000 users across 43 states. Twentyeight Health raised $10M in a Series A, bringing its total capital raised to $25M. The company intends to use the funds to expand operations and accelerate product development. Bruno Van Tuykom serves as CEO. Twentyeight Health operates a women’s virtual healthcare platform focused on sexual and reproductive care, accepting Medicaid and partnering with culturally competent clinicians. The platform is bilingual (English and Spanish) and aims to serve medically underserved, low-income, and non-urban populations. Since founding in 2018, the company has expanded from six to 34 states and now covers more than 85% of women of reproductive age in the U.S. It has helped over 60,000 individuals access care, with 55% of users on Medicaid, 58% identifying as BIPOC, and 60% living in non-urban areas; 63% of its birth-control users previously lacked access to prescriptions. The company offers free birth control to uninsured users through a partnership with the Contraceptive Access Fund of Bedsider and donates 2% of revenues to related organizations. With recent funding, Twentyeight Health plans to expand nonprofit partnerships, grow its services and footprint, and improve the quality of its telehealth offerings. Twentyeight Health offers telemedicine reproductive-health services focused on contraception, providing online medical questionnaires reviewed by U.S. board-certified doctors and access to more than 100 FDA-approved birth control options. Customers receive shipments within three days and ongoing care via audio consultations and doctor follow-up messages. The company emphasizes serving Medicaid, underinsured, and uninsured women and works with partners such as Bottomless Closet and eight CUNY colleges to reach underserved populations. Twentyeight Health is the only telemedicine contraception provider noted in the article that accepts Medicaid and also partners with Bedsider’s Contraceptive Access Fund to provide free birth control to uninsured patients. The company donates 2% of its revenue to Bedsider and the National Institute for Reproductive Health. Launched in 2018, Twentyeight Health currently operates across Florida, Maryland, New York, New Jersey, North Carolina, and Pennsylvania and plans to use new funding to expand services across the U.S.

Led · Seed · Dec 2022

Aja Labs is a materials innovation company creating biomaterial hair fibers from plant material and commercializing consumer products under the Nourie brand. Its first product line includes patent-pending hair extensions with a time-release function that delivers a nutrient complex over time during wear. The company is moving from development toward commercialization and intends to use the new funding to accelerate that transition. Aja Labs was founded in 2020 and is based in Raleigh, NC. The founding team includes CEO and Founder Osahon Ojeaga and Chief Scientific Officer and Co-founder Dr. Mary Moore, a materials and polymer engineer. The company raised a seed round in January 2022 to support product development and market launch.